China
Africa
Explore chapters and articles related to this topic
Yellow Fever
Published in Rae-Ellen W. Kavey, Allison B. Kavey, Viral Pandemics, 2020
Rae-Ellen W. Kavey, Allison B. Kavey
The vaccines used came from the global stockpile co-managed by Médecins Sans Frontières (MSF), the International Federation of the Red Cross and Red Crescent Societies (IFRC), UNICEF and the WHO. In the first 6 months of 2016 alone, these partners delivered more than 19 million doses of the vaccine – more than three times the six million doses usually put aside for a possible outbreak. GAVI financed a significant proportion of the vaccines. Because the vaccine supply was so limited, WHO used a fractional dose strategy based on studies showing that one fifth of the usual dose of the yellow fever vaccine will provide immunity for at least a year – enough time to achieve the critical level of resistance needed to stop the outbreak.56 A massive training and community engagement effort resulted in 30 million people being vaccinated across the two countries. The campaign was at least temporarily successful with no reports of suspected cases in Angola or the DRC after September 2016.57
Information on level of drugs into breastmilk
Published in Wendy Jones, Breastfeeding and Medication, 2018
Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC), Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, 2010;59(RR-7):1–27.
Travel Health Considerations
Published in Akshaya Neil Arya, Preparing for International Health Experiences, 2017
Yellow fever vaccination is unique in that international health regulations outline the requirements for proof of vaccination when travelling between countries of yellow fever risk. It is important to consider the whole travel itinerary, since travel to a non-yellow fever endemic country with transit, even only at the airport, through a country designated as having yellow fever vaccine requirements, such as Kenya, will require proof of vaccine. In Canada and the United States, this vaccination is only available at centres designated by Public Health Agency of Canada and Centers for Disease Control, respectively, in order to meet the requirements of the International Health Regulations (PHAC, 2012). World Health Organization (WHO) updated yellow fever vaccination guidelines in 2011, including classification of geographic areas of risk and revisions of maps to illustrate vaccination recommendations rather than yellow fever risk (CATMAT, 2013). It is important for each traveller to ensure that they are compliant with the requirements for yellow fever vaccine at their destination, and that they also include any transit through yellow fever designated countries. Failure to have properly documented vaccine may result in denial of entry or vaccine administration at the destination.
Anterior and Intermediate Uveitis Following Yellow Fever Vaccination with Fractional Dose: Case Reports
Published in Ocular Immunology and Inflammation, 2019
Ana Luiza Biancardi, Haroldo Vieira de Moraes
Yellow fever vaccine induces strong activation of the cellular and humoral immune responses, which can result in a molecular mimicry that may lead to immune cross-reactivity triggering an autoimmune disease like anterior or intermediate uveitis. A limitation of this report must be discussed. There is a temporal relationship between vaccination and the occurrence of uveitis, but a causal relationship remains presumed. In conclusion, a warning should be given to physicians, specially those that work in endemic areas, as well as those that deal with international travelers going to affected areas, about the possibility of eye inflammation following the yellow fever vaccination with fractional dose.
The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences
Published in Expert Review of Vaccines, 2018
Clarissa de Castro Ferreira, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhāes, Christiane Costa-Pereira, Cleandro Pires de Albuquerque, Luciana Feitosa Muniz, Talita Yokoy de Souza, Ana Cristina Vanderley Oliveira, Olindo Assis Martins-Filho, Licia Maria Henrique da Mota
The yellow fever vaccine is a live-attenuated virus vaccine that is considered one of the most efficient vaccines produced to date. The vaccine is one of the most applied vaccines worldwide, with more than 600 million doses distributed [1]. The vaccine was discovered by Max Theiler et al. in 1937 from a virus isolated from an African patient who was cured [2,3]. Theiler subjected the virus to 176 passages in monkey, mouse, and chicken cell cultures, which led to viral attenuation but maintained the virus’s immunogenicity [2,4–6]. This original strain was named 17D.
Corneal Graft Rejection after Yellow Fever Vaccine: A Case Report
Published in Ocular Immunology and Inflammation, 2022
Roberto Vignapiano, Lidia Vicchio, Eleonora Favuzza, Michela Cennamo, Rita Mencucci
Yellow fever vaccine is a very safe and efficacious vaccine but the occurrence of vaccine-related rejection may be more frequent than reported.6,25–27 An awareness of both patients and ophthalmologists is required, especially for those that work in endemic areas or deal with international travelers going to affected areas.